Your browser doesn't support javascript.
Application of convalescent plasma from patients with COVID-19 treatment of Coronavirus Disease 2019
Chinese Journal of Biologicals ; 34(5):607-611, 2021.
Article in Chinese | EMBASE | ID: covidwho-2126222
ABSTRACT
The pandemic of Coronavirus Disease 2019 (COVID-19) in 2020 has posed a great challenge to global public health resources. Since there are no specific antiviral drugs at present, convalescent plasma (CP) from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Preliminary studies have shown that the CP containing high titer neutralizing antibody against SARS-CoV-2 is safe and promising in blocking viral replication and improving patients'clinical symptoms. In this article, we briefly summarize the application of CP in treatment of COVID-19, and explores possible action mechanism, relevant clinical research and possible influencing factors of clinical effect, which may be helpful to the rational application of CP in treatment of COVID-19. Copyright © 2021 Changchun Institute of Biological Products. All rights reserved.
Keywords
Search on Google
Collection: Databases of international organizations Database: EMBASE Language: Chinese Journal: Chinese Journal of Biologicals Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: EMBASE Language: Chinese Journal: Chinese Journal of Biologicals Year: 2021 Document Type: Article